Allison L Kuipers1, Iva Miljkovic2, J Jeffery Carr3, James G Terry3, Cara S Nestlerode2, Yaorong Ge4, Clareann H Bunker2, Alan L Patrick5, Joseph M Zmuda6. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: kuipers@pitt.edu. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Radiology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Software and Information Sciences, University of North Carolina, Charlotte, NC, USA. 5. Tobago Health Studies Office, Scarborough, Tobago, Trinidad and Tobago. 6. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
OBJECTIVE: Sclerostin, a Wingless (Wnt) pathway antagonist, is an established regulator of bone mineralization in humans but its potential importance in the regulation of vascular calcification is less clear. Therefore, our objective was to assess the relationship of serum sclerostin levels with coronary and aortic artery calcification (CAC and AAC, respectively) in Afro-Caribbean men on the island of Tobago. METHODS: Serum sclerostin levels and computed tomography of CAC and AAC were measured in 191 men (age mean(SD): 62.9(8.0)years) recruited without regard to health status. Multivariable logistic regression models were used to assess the cross-sectional association of sclerostin with prevalent arterial calcification. RESULTS: Mean(SD) sclerostin was 45.2 pmol/L (15.6 pmol/L). After adjusting for risk factors including age, physical and lifestyle characteristics, comorbidities, lipoproteins and kidney function, 1 SD greater sclerostin level was associated with a 1.61-times (95%CI 1.02-2.53) greater odds of having CAC. Sclerostin was not associated with AAC in any model. CONCLUSIONS: This is the first study to show that, among Afro-Caribbean men, greater serum sclerostin concentrations were associated with prevalence and extent of CAC. Further studies are needed to better define the role of the Wnt signaling pathway in arterial calcification in humans.
OBJECTIVE:Sclerostin, a Wingless (Wnt) pathway antagonist, is an established regulator of bone mineralization in humans but its potential importance in the regulation of vascular calcification is less clear. Therefore, our objective was to assess the relationship of serum sclerostin levels with coronary and aortic artery calcification (CAC and AAC, respectively) in Afro-Caribbean men on the island of Tobago. METHODS: Serum sclerostin levels and computed tomography of CAC and AAC were measured in 191 men (age mean(SD): 62.9(8.0)years) recruited without regard to health status. Multivariable logistic regression models were used to assess the cross-sectional association of sclerostin with prevalent arterial calcification. RESULTS: Mean(SD) sclerostin was 45.2 pmol/L (15.6 pmol/L). After adjusting for risk factors including age, physical and lifestyle characteristics, comorbidities, lipoproteins and kidney function, 1 SD greater sclerostin level was associated with a 1.61-times (95%CI 1.02-2.53) greater odds of having CAC. Sclerostin was not associated with AAC in any model. CONCLUSIONS: This is the first study to show that, among Afro-Caribbean men, greater serum sclerostin concentrations were associated with prevalence and extent of CAC. Further studies are needed to better define the role of the Wnt signaling pathway in arterial calcification in humans.
Authors: S Thambiah; R Roplekar; P Manghat; I Fogelman; W D Fraser; D Goldsmith; Geeta Hampson Journal: Calcif Tissue Int Date: 2012-04-21 Impact factor: 4.333
Authors: M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan Journal: Am J Hum Genet Date: 2001-02-09 Impact factor: 11.025
Authors: Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow Journal: Am J Med Genet Date: 2002-06-15
Authors: Sabine R Zwakenberg; Yvonne T van der Schouw; Casper G Schalkwijk; Annemieke M W Spijkerman; Joline W J Beulens Journal: Cardiovasc Diabetol Date: 2018-03-23 Impact factor: 9.951
Authors: Monika Frysz; Ingrid Gergei; Hubert Scharnagl; George Davey Smith; Jie Zheng; Deborah A Lawlor; Markus Herrmann; Winfried Maerz; Jon H Tobias Journal: J Bone Miner Res Date: 2021-12-09 Impact factor: 6.390